Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Licenses Fosamax for Generic Sale | Contract Pharma

What are you searching for?

Sign in
Breaking News

Merck Licenses Fosamax for Generic Sale

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck has signed a licensing agreement for an authorized generic form of its osteoporosis drug, Fosamax, which will be available after the U.S. patent expires in February 2007. The drug’s global annual sales are approximately $3 billion.
   
“We can confirm an authorized generic deal for Fosamax has been signed, although specific details of the deal are proprietary,” said Merck spokesman Ron Rogers.  
   
The agreement allows Merck to maintain some of its revenues from the drug after patent protection expires and becomes open to competition from generics.  

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters